PMID- 32380969
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 7
TI  - Dynamics of the bacterial gut microbiota in preterm and term infants after 
      intravenous amoxicillin/ceftazidime treatment.
PG  - 195
LID - 10.1186/s12887-020-02067-z [doi]
LID - 195
AB  - BACKGROUND: It is important to understand the consequences of pre-emptive 
      antibiotic treatment in neonates, as disturbances in microbiota development 
      during this key developmental time window might affect early and later life 
      health outcomes. Despite increasing knowledge regarding the detrimental effect of 
      antibiotics on the gut microbiota, limited research focussed on antibiotic 
      treatment duration. We determined the effect of short and long 
      amoxicillin/ceftazidime administration on gut microbiota development during the 
      immediate postnatal life of preterm and term infants. METHODS: Faeces was 
      collected from 63 (pre) term infants at postnatal weeks one, two, three, four and 
      six. Infants received either no (control), short-term (ST) or long-term (LT) 
      postpartum amoxicillin/ceftazidime treatment. RESULTS: Compared to control 
      infants, ST and LT infants' microbiota contained significantly higher abundance 
      of Enterococcus during the first two postnatal weeks at the expense of 
      Bifidobacterium and Streptococcus. Short and long antibiotic treatment both 
      allowed for microbiota restoration within the first six postnatal weeks. However, 
      Enterococcus and Bifidobacterium abundances were affected in fewer ST than LT 
      infants. CONCLUSIONS: Intravenous amoxicillin/ceftazidime administration affects 
      intestinal microbiota composition by decreasing the relative abundance of 
      Escherichia-Shigella and Streptococcus, while increasing the relative abundance 
      of Enterococcus and Lactobacillus species during the first two postnatal weeks. 
      Thriving of enterococci at the expense of bifidobacteria and streptococci should 
      be considered as aspect of the cost-benefit determination for antibiotic 
      prescription.
FAU - Zwittink, Romy D
AU  - Zwittink RD
AD  - Laboratory of Microbiology, Wageningen University, Stippeneng 4, 6708WE, 
      Wageningen, The Netherlands.
FAU - van Zoeren-Grobben, Diny
AU  - van Zoeren-Grobben D
AD  - Princess Amalia Dpt of Paediatrics, Dpt of Neonatology, Isala, Zwolle, The 
      Netherlands.
FAU - Renes, Ingrid B
AU  - Renes IB
AD  - Danone Nutricia Research, Utrecht, The Netherlands.
FAU - van Lingen, Richard A
AU  - van Lingen RA
AD  - Princess Amalia Dpt of Paediatrics, Dpt of Neonatology, Isala, Zwolle, The 
      Netherlands.
FAU - Norbruis, Obbe F
AU  - Norbruis OF
AD  - Princess Amalia Dpt of Paediatrics, Dpt of Neonatology, Isala, Zwolle, The 
      Netherlands.
FAU - Martin, Rocio
AU  - Martin R
AD  - Danone Nutricia Research, Utrecht, The Netherlands.
FAU - Groot Jebbink, Liesbeth J
AU  - Groot Jebbink LJ
AD  - Princess Amalia Dpt of Paediatrics, Dpt of Neonatology, Isala, Zwolle, The 
      Netherlands.
FAU - Knol, Jan
AU  - Knol J
AD  - Laboratory of Microbiology, Wageningen University, Stippeneng 4, 6708WE, 
      Wageningen, The Netherlands.
AD  - Danone Nutricia Research, Utrecht, The Netherlands.
FAU - Belzer, Clara
AU  - Belzer C
AD  - Laboratory of Microbiology, Wageningen University, Stippeneng 4, 6708WE, 
      Wageningen, The Netherlands. clara.belzer@wur.nl.
LA  - eng
PT  - Journal Article
DEP - 20200507
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
RN  - 0 (RNA, Ribosomal, 16S)
RN  - 804826J2HU (Amoxicillin)
RN  - 9M416Z9QNR (Ceftazidime)
SB  - IM
MH  - Amoxicillin
MH  - Ceftazidime
MH  - Feces
MH  - Female
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infant, Premature
MH  - RNA, Ribosomal, 16S
PMC - PMC7204001
OTO - NOTNLM
OT  - Antibiotics
OT  - Gut microbiota
OT  - Infant
OT  - Next generation sequencing
OT  - Preterm
COIS- The authors IBR, RM and JK are employees of Danone Nutricia Research. The authors 
      RDZ and CB were financially supported by Danone Nutricia Research.
EDAT- 2020/05/10 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/05/07
CRDT- 2020/05/09 06:00
PHST- 2018/12/18 00:00 [received]
PHST- 2020/04/01 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/05/07 00:00 [pmc-release]
AID - 10.1186/s12887-020-02067-z [pii]
AID - 2067 [pii]
AID - 10.1186/s12887-020-02067-z [doi]
PST - epublish
SO  - BMC Pediatr. 2020 May 7;20(1):195. doi: 10.1186/s12887-020-02067-z.